Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 350,000 ordinary shares of 25 pence each.
- Purchase Price: 1,428.4394 pence per share.
- Treasury Shares Held: 197,091,678 shares (post-transaction).
- Shares in Issue: 5,789,141,868 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on September 26, 2006, authorized by shareholders at the Annual General Meeting on May 17, 2006. The purchased shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 350,000 share repurchase based on the stated price of 1,428.4394 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.